IL89503A - Taxol derivatives, pharmaceutical compositions containing the same and process for the preparation thereof - Google Patents

Taxol derivatives, pharmaceutical compositions containing the same and process for the preparation thereof

Info

Publication number: IL89503A
Authority: IL; Israel
Prior art keywords: taxol; derivative; salt; carbons; benzyl
Prior art date: 1988-03-07

Application number

IL8950389A

Other languages

English (en)

Other versions

IL89503A0 (en

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-07

Filing date

1989-03-06

Publication date

1994-02-27

1989-03-06 Application filed by Us Health filed Critical Us Health

1989-09-10 Publication of IL89503A0 publication Critical patent/IL89503A0/xx

1994-02-27 Publication of IL89503A publication Critical patent/IL89503A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 4
238000000034 method Methods 0.000 title abstract description 15
150000004579 taxol derivatives Chemical class 0.000 title abstract description 7
238000002360 preparation method Methods 0.000 title description 4
230000008569 process Effects 0.000 title description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 7
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical class O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 24
229930012538 Paclitaxel Natural products 0.000 claims description 22
229960001592 paclitaxel Drugs 0.000 claims description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 11
-1 dimethylamino-ethyl Chemical group 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 3
125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
150000004820 halides Chemical class 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
101100220369 Mus musculus Csgalnact1 gene Proteins 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 18
239000002253 acid Substances 0.000 description 15
206010028980 Neoplasm Diseases 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 7
239000000243 solution Substances 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
239000002585 base Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000000047 product Substances 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
150000008064 anhydrides Chemical class 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
RBNOJYDPFALIQZ-LAVNIZMLSA-N 2'-succinyltaxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](OC(=O)CCC(O)=O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RBNOJYDPFALIQZ-LAVNIZMLSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000001382 Experimental Melanoma Diseases 0.000 description 3
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
239000000376 reactant Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000003900 succinic acid esters Chemical class 0.000 description 2
229940014800 succinic anhydride Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
WNLWBCIUNCAMPH-UHFFFAOYSA-N 2-n,2-n-dimethylpropane-1,2-diamine Chemical compound NCC(C)N(C)C WNLWBCIUNCAMPH-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
241001116500 Taxus Species 0.000 description 1
241000202349 Taxus brevifolia Species 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
ZOMZNNQGMGBLHO-UHFFFAOYSA-N heptane-1,5-diamine Chemical compound CCC(N)CCCCN ZOMZNNQGMGBLHO-UHFFFAOYSA-N 0.000 description 1
XTBMQKZEIICCCS-UHFFFAOYSA-N hexane-1,5-diamine Chemical compound CC(N)CCCCN XTBMQKZEIICCCS-UHFFFAOYSA-N 0.000 description 1
XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000008149 soap solution Substances 0.000 description 1
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Medicinal Preparation (AREA)

IL8950389A 1988-03-07 1989-03-06 Taxol derivatives, pharmaceutical compositions containing the same and process for the preparation thereof IL89503A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/165,173 US4942184A (en)	1988-03-07	1988-03-07	Water soluble, antineoplastic derivatives of taxol

Publications (2)

Publication Number	Publication Date
IL89503A0 IL89503A0 (en)	1989-09-10
IL89503A true IL89503A (en)	1994-02-27

Family

ID=22597770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8950389A IL89503A (en)	1988-03-07	1989-03-06	Taxol derivatives, pharmaceutical compositions containing the same and process for the preparation thereof

Country Status (9)

Country	Link
US (1)	US4942184A (de)
EP (1)	EP0406274B1 (de)
JP (1)	JP2680152B2 (de)
AT (1)	ATE109002T1 (de)
AU (1)	AU620605B2 (de)
CA (1)	CA1330436C (de)
DE (1)	DE68917129T2 (de)
IL (1)	IL89503A (de)
WO (1)	WO1989008453A1 (de)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4960790A (en) *	1989-03-09	1990-10-02	University Of Kansas	Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
MY110249A (en) *	1989-05-31	1998-03-31	Univ Florida State	Method for preparation of taxol using beta lactam
US5278324A (en) *	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
US5059699A (en) *	1990-08-28	1991-10-22	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
US5380916A (en) *	1990-11-02	1995-01-10	University Of Florida	Method for the isolation and purification of taxane derivatives
US5194635A (en) *	1991-03-18	1993-03-16	Virginia Tech Intellectual Properties, Inc.	Rearranged taxol compounds and method of using in testing of in vivo activity
US6150398A (en) *	1991-05-08	2000-11-21	The United States Of America As Represented By The Department Of Health And Human Services	Methods for the treatment of cancer
US5334093A (en) *	1991-05-10	1994-08-02	Deere & Company	Detachable covers for an axial separator
CA2072400C (en) *	1991-07-05	2003-08-19	Jayaprakash B. Nair	Supercritical extraction of taxanes
US5338872A (en) *	1993-01-15	1994-08-16	Florida State University	Process for the preparation of 10-desacetoxybaccatin III and 10-desacetoxytaxol and derivatives thereof
US6794523B2 (en)	1991-09-23	2004-09-21	Florida State University	Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US5998656A (en) *	1991-09-23	1999-12-07	Florida State University	C10 tricyclic taxanes
IL103191A (en) *	1991-09-23	2001-07-24	Univ Florida State	Semi-synthesis of taxane derivatives using metal alkoxides and beta-lactams and intermediates thereof
US5728850A (en) *	1991-09-23	1998-03-17	Florida State University	Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US5350866A (en) *	1991-09-23	1994-09-27	Bristol-Myers Squibb Company	10-desacetoxytaxol derivatives
US5654447A (en) *	1991-09-23	1997-08-05	Florida State University	Process for the preparation of 10-desacetoxybaccatin III
US6495704B1 (en)	1991-09-23	2002-12-17	Florida State University	9-desoxotaxanes and process for the preparation of 9-desoxotaxanes
US5489601A (en) *	1991-09-23	1996-02-06	Florida State University	Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5284865A (en)	1991-09-23	1994-02-08	Holton Robert A	Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5714513A (en) *	1991-09-23	1998-02-03	Florida State University	C10 taxane derivatives and pharmaceutical compositions
US5229526A (en) *	1991-09-23	1993-07-20	Florida State University	Metal alkoxides
US5430160A (en) *	1991-09-23	1995-07-04	Florida State University	Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5739362A (en) *	1991-09-23	1998-04-14	Florida State University	Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5227400A (en) *	1991-09-23	1993-07-13	Florida State University	Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5283253A (en) *	1991-09-23	1994-02-01	Florida State University	Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US6028205A (en) *	1991-09-23	2000-02-22	Florida State University	C2 tricyclic taxanes
US5250683A (en) *	1991-09-23	1993-10-05	Florida State University	Certain substituted taxanes and pharmaceutical compositions containing them
US5728725A (en) *	1991-09-23	1998-03-17	Florida State University	C2 taxane derivaties and pharmaceutical compositions containing them
US7074945B2 (en) *	1991-09-23	2006-07-11	Florida State University	Metal alkoxide taxane derivatives
US6018073A (en) *	1991-09-23	2000-01-25	Florida State University	Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US6335362B1 (en)	1991-09-23	2002-01-01	Florida State University	Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
US5710287A (en) *	1991-09-23	1998-01-20	Florida State University	Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
US5274124A (en) *	1991-09-23	1993-12-28	Florida State University	Metal alkoxides
US5243045A (en) *	1991-09-23	1993-09-07	Florida State University	Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5811447A (en) *	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) *	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
ES2230790T3 (es) *	1992-01-15	2005-05-01	E.R. SQUIBB & SONS, INC.	Procedimientos enzimaticos para la resolucion de mezclas enantiomericas de compuestos utiles como intermedios en la preparacion de taxanos.
US5272171A (en) *	1992-02-13	1993-12-21	Bristol-Myers Squibb Company	Phosphonooxy and carbonate derivatives of taxol
US5445809A (en) *	1992-03-03	1995-08-29	Research And Development Institute At Montana State University	Production of taxol from the yew tree
US5451392A (en) *	1992-03-03	1995-09-19	The Research And Development Institute At Montana State University	Production of taxol
US5254703A (en) *	1992-04-06	1993-10-19	Florida State University	Semi-synthesis of taxane derivatives using metal alkoxides and oxazinones
JPH069600A (ja) *	1992-05-06	1994-01-18	Bristol Myers Squibb Co	タクソールのベンゾエート誘導体
AU4242993A (en) *	1992-05-21	1993-12-13	Penn State Research Foundation, The	Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
FR2691460B1 (fr) *	1992-05-21	1994-07-22	Rhone Poulenc Rorer Sa	Nouveaux derives du taxane, leur preparation et les compositions qui les contiennent.
US5364947A (en) *	1992-07-02	1994-11-15	Hauser Chemical Research, Inc.	Process for separating cephalomannine from taxol using ozone and water-soluble hydrazines or hydrazides
US5614549A (en) *	1992-08-21	1997-03-25	Enzon, Inc.	High molecular weight polymer-based prodrugs
WO1994005282A1 (en) *	1992-09-04	1994-03-17	The Scripps Research Institute	Water soluble taxol derivatives
FR2696464B1 (fr) *	1992-10-05	1994-11-10	Rhone Poulenc Rorer Sa	Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5411984A (en) *	1992-10-16	1995-05-02	Virginia Tech Intellectual Properties, Inc.	Water soluble analogs and prodrugs of taxol
EP0667772B9 (de) *	1992-11-13	2004-08-04	Florida State University	Taxane, die eine alkyl-substituierte seitenkette haben, und diese enthaltende pharmazeutische zusammensetzungen
CA2149150C (en) *	1992-11-27	2000-08-01	David R. Carver	Injectable taxol composition with improved stability
US5356927A (en) *	1992-12-02	1994-10-18	Thomas Jefferson University	Methods of treating plasmodium and babesia parasitic infections
AU5735094A (en) *	1992-12-02	1994-06-22	Thomas Jefferson University	Methods of killing protozoal parasites
US5279949A (en) *	1992-12-07	1994-01-18	Board Of Trustees Operating Michigan State University	Process for the isolation and purification of taxol and taxanes from Taxus spp
IL107950A (en) *	1992-12-15	2001-04-30	Upjohn Co	7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5973160A (en)	1992-12-23	1999-10-26	Poss; Michael A.	Methods for the preparation of novel sidechain-bearing taxanes
US5646176A (en) *	1992-12-24	1997-07-08	Bristol-Myers Squibb Company	Phosphonooxymethyl ethers of taxane derivatives
NO310238B1 (no) *	1992-12-24	2001-06-11	Bristol Myers Squibb Co	Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater
RU2136673C1 (ru) *	1992-12-24	1999-09-10	Бристоль-Мейерз Сквибб Компани	Фосфонооксиметиловые эфиры таксановых производных, промежуточные соединения, противоопухолевая фармацевтическая композиция, способ ингибирования роста опухоли у млекопитающих
IL108444A0 (en) *	1993-01-29	1994-04-12	Univ Florida State	C2 taxane derivatives and pharmaceutical compositions containing them
EP0688212B1 (de) *	1993-03-05	2002-06-12	Florida State University	C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
US6710191B2 (en) *	1993-03-05	2004-03-23	Florida State University	9β-hydroxytetracyclic taxanes
DE69432140T2 (de) *	1993-03-05	2003-07-31	Florida State University, Tallahassee	Verfahren zur Herstellung von 9-Desoxotaxanen
CA2092271C (en) *	1993-03-09	2009-10-13	Eddie Reed	Use of g-csf for treating taxol side-effects
WO1994020089A1 (en) *	1993-03-09	1994-09-15	Enzon, Inc.	Taxol-based compositions with enhanced bioactivity
US5547981A (en) *	1993-03-09	1996-08-20	Enzon, Inc.	Taxol-7-carbazates
DK1227093T3 (da) *	1993-03-22	2005-08-29	Univ Florida State	Beta-lactamer, der kan anvendes til fremstilling af taxaner med en furyl- eller thienylsubstitueret sidekæde
ATE195421T1 (de) *	1993-03-22	2000-09-15	Univ Florida State	Taxane mit amino-substituierter seitenkette
US5336684A (en) *	1993-04-26	1994-08-09	Hauser Chemical Research, Inc.	Oxidation products of cephalomannine
IT1261667B (it) *	1993-05-20	1996-05-29		Tassano ad attivita' antitumorale.
DE69424166T2 (de) *	1993-06-11	2000-10-05	Pharmacia & Upjohn Co., Kalamazoo	Delta 6, 7-taxolen, antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
US5468769A (en) *	1993-07-15	1995-11-21	Abbott Laboratories	Paclitaxel derivatives
DE69403966T3 (de)	1993-07-19	2008-04-17	Angiotech Pharmaceuticals, Inc., Vancouver	Anti-angiogene mittel und verfahren zu deren verwendung
AU7476894A (en) *	1993-07-29	1995-02-28	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
CA2129288C (en) *	1993-08-17	2000-05-16	Jerzy Golik	Phosphonooxymethyl esters of taxane derivatives
US5880131A (en) *	1993-10-20	1999-03-09	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5965566A (en) *	1993-10-20	1999-10-12	Enzon, Inc.	High molecular weight polymer-based prodrugs
WO1995011020A1 (en) *	1993-10-20	1995-04-27	Enzon, Inc.	2'- and/or 7- substituted taxoids
US5415869A (en) *	1993-11-12	1995-05-16	The Research Foundation Of State University Of New York	Taxol formulation
EP0739339A1 (de)	1994-01-11	1996-10-30	The Scripps Research Institute	Variation von taxo-diterpenoiden zwischen aktiven formen mit geringen loslichkeit und inaktiven formen mit hohen aktiven formen
PT738148E (pt)	1994-01-11	2002-11-29	Scripps Research Inst	Nanoestruturas taxo-diterpenoides auto-construidas
US5731334A (en) *	1994-01-11	1998-03-24	The Scripps Research Institute	Method for treating cancer using taxoid onium salt prodrugs
IL127598A (en) *	1994-01-28	2003-04-10	Upjohn Co	Process for preparing isotaxol analogs
GB9405400D0 (en) *	1994-03-18	1994-05-04	Erba Carlo Spa	Taxane derivatives
US5508447A (en) *	1994-05-24	1996-04-16	Board Of Regents, The University Of Texas System	Short synthetic route to taxol and taxol derivatives
CA2192373A1 (en) *	1994-06-09	1995-12-14	Hirofumi Terasawa	Deacetoxytaxol derivative
USRE38424E1 (en)	1994-11-21	2004-02-10	The United States Of America As Represented By The Department Of Health And Human Services	Method for treating taxol side-effects with G-CSF
US5489589A (en) *	1994-12-07	1996-02-06	Bristol-Myers Squibb Company	Amino acid derivatives of paclitaxel
CA2170661A1 (en)	1995-03-22	1996-09-23	John K. Thottathil	Novel methods for the preparation of taxanes using oaxzolidine intermediates
US5801191A (en) *	1995-06-01	1998-09-01	Biophysica Foundation	Taxoids
AU716005B2 (en)	1995-06-07	2000-02-17	Cook Medical Technologies Llc	Implantable medical device
CA2240468A1 (en) *	1995-09-11	1997-03-20	Peter C. Michels	Biocatalytic methods for synthesizing and identifying biologically active compounds
US5654448A (en) *	1995-10-02	1997-08-05	Xechem International, Inc.	Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
US5854278A (en) *	1995-12-13	1998-12-29	Xechem International, Inc.	Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US6177456B1 (en)	1995-10-02	2001-01-23	Xechem International, Inc.	Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
US5807888A (en) *	1995-12-13	1998-09-15	Xechem International, Inc.	Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
US5840748A (en) *	1995-10-02	1998-11-24	Xechem International, Inc.	Dihalocephalomannine and methods of use therefor
US5760072A (en) *	1995-12-29	1998-06-02	Pharmachemie B.V.	Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
US6441025B2 (en) *	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
PL189698B1 (pl)	1996-03-12	2005-09-30	Pg Txl Co	Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
IL126856A0 (en)	1996-05-06	1999-09-22	Univ Florida State	1-Deoxy baccatin iii 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
DE69715417T2 (de) *	1996-05-08	2003-06-05	Pharmacia & Upjohn Co., Kalamazoo	Oxazolidinester
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
WO1997045105A1 (en) *	1996-05-24	1997-12-04	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating or preventing diseases of body passageways
US5635531A (en) *	1996-07-08	1997-06-03	Bristol-Myers Squibb Company	3'-aminocarbonyloxy paclitaxels
BR9710366A (pt) *	1996-07-15	1999-08-17	Yakult Honsha Kk	Derivados de taxane e drogas que os contêm
GB9705903D0 (en)	1997-03-21	1997-05-07	Elliott Gillian D	VP22 Proteins and uses thereof
JPH1192468A (ja) *	1997-09-17	1999-04-06	Yakult Honsha Co Ltd	新規なタキサン誘導体
IL131217A0 (en) *	1998-03-10	2001-01-28	Napro Biotherapeutics Inc	Novel methods and compositions for delivery of taxanes
US5981564A (en) *	1998-07-01	1999-11-09	Universite Laval	Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US6303589B1 (en)	1998-12-08	2001-10-16	Micro Flo Company	Pentacyclic triterpenes
US20030054977A1 (en) *	1999-10-12	2003-03-20	Cell Therapeutics, Inc.	Manufacture of polyglutamate-therapeutic agent conjugates
US20020077290A1 (en) *	2000-03-17	2002-06-20	Rama Bhatt	Polyglutamic acid-camptothecin conjugates and methods of preparation
US6395771B1 (en) *	2000-05-31	2002-05-28	Dabur Research Foundation	Paclitaxel derivatives for the treatment of cancer
US6638742B1 (en)	2000-07-07	2003-10-28	University Of Portland	Methods for obtaining taxanes
JP2004525860A (ja)	2000-09-22	2004-08-26	ブリストル−マイヤーズスクイブカンパニー	併用化学療法剤の毒性を低下させる方法
JP2004536026A (ja) *	2000-11-28	2004-12-02	トランスフォームファーマシューティカルズ，インコーポレーティッド．	パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20030157170A1 (en) *	2001-03-13	2003-08-21	Richard Liggins	Micellar drug delivery vehicles and precursors thereto and uses thereof
EP1418945A2 (de) *	2001-03-13	2004-05-19	Angiotech Pharmaceuticals, Inc.	Mizellare arzneimittelabgabe vehikel und ihre anwendungen
JP2004532847A (ja) *	2001-04-20	2004-10-28	ザユニヴァーシティオヴブリティッシュコロンビア	疎水性薬物のためのミセル薬物送達システム
TR201809678T4 (tr) *	2001-06-26	2018-07-23	Amgen Fremont Inc	Opgl ye karşi antikorlar.
EP1435965A4 (de) *	2001-09-26	2005-09-21	Intermune Inc	Pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
CA2466851C (en) *	2001-11-26	2012-09-11	Supergen, Inc.	Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
AU2002357012A1 (en) *	2001-11-27	2003-06-10	Transform Pharmaceuticals, Inc.	Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2003047508A2 (en) *	2001-11-30	2003-06-12	Bristol-Myers Squibb Company	Paclitaxel solvates
US20030216758A1 (en) *	2001-12-28	2003-11-20	Angiotech Pharmaceuticals, Inc.	Coated surgical patches
US7176325B2 (en) *	2002-04-05	2007-02-13	Natural Pharmaceuticals, Inc.	Selective acylation of secondary hydroxyl groups
US20040047835A1 (en) *	2002-09-06	2004-03-11	Cell Therapeutics, Inc.	Combinatorial drug therapy using polymer drug conjugates
US7326421B2 (en) *	2002-10-21	2008-02-05	Kensey Nash Corporation	Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
WO2004060346A2 (en)	2002-12-30	2004-07-22	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
ATE512674T1 (de) *	2003-01-06	2011-07-15	Angiochem Inc	Angiopep-1, verwandte verbindungen, und deren verwnedungen
WO2005077385A2 (en)	2004-02-18	2005-08-25	Gpc Biotech Ag	Methods for treating resistant or refractory tumors
US8003122B2 (en) *	2004-03-31	2011-08-23	Cordis Corporation	Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) *	2004-03-31	2010-12-07	Cordis Corporation	Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en)	2004-06-02	2011-08-02	Cordis Corporation	Injectable formulations of taxanes for cad treatment
AU2005251691A1 (en) *	2004-05-17	2005-12-22	Tekmira Pharmaceuticals Corporation	Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
EP2027853A3 (de)	2004-06-18	2011-01-05	Agennix USA Inc.	Kinase-Hemmer zur Behandlung von Krebs
US20060135468A1 (en)	2004-09-02	2006-06-22	Bionaut Pharmaceuticals, Inc.	Treatment of refractory cancers using NA+/K+ ATPase inhibitors
USH2260H1 (en)	2005-02-17	2011-07-05	Angiotech International Ag	Stents combined with paclitaxel derivatives
MX2007010113A (es) *	2005-02-18	2007-12-07	Angiochem Inc	Polipeptidos de aprotinina para transportar un compuesto a traves de la barrera hematoencefalica.
US20090016959A1 (en) *	2005-02-18	2009-01-15	Richard Beliveau	Delivery of antibodies to the central nervous system
PL2233156T3 (pl)	2005-07-15	2013-09-30	Angiochem Inc	Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US20070073385A1 (en) *	2005-09-20	2007-03-29	Cook Incorporated	Eluting, implantable medical device
KR20080074202A (ko) *	2005-12-06	2008-08-12	셀 쎄러퓨틱스 인코포레이티드	에스트로겐 암 요법
PL217731B1 (pl)	2006-06-01	2014-08-29	Tomasz Byrski	Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP2043704B2 (de)	2006-06-30	2017-04-19	Cook Medical Technologies LLC	Verfahren zur herstellung und modifizierung von taxan-beschichtungen für implantierbare medizinische vorrichtungen
US20080241215A1 (en) *	2007-03-28	2008-10-02	Robert Falotico	Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US9365634B2 (en) *	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8409601B2 (en)	2008-03-31	2013-04-02	Cordis Corporation	Rapamycin coated expandable devices
US8420110B2 (en)	2008-03-31	2013-04-16	Cordis Corporation	Drug coated expandable devices
CA2721153C (en) *	2008-04-10	2018-10-02	Abraxis Bioscience, Llc	Compositions of hydrophobic taxane derivatives and uses thereof
CN102026667B (zh) *	2008-04-18	2014-06-25	安吉奥开米公司	紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
US8273404B2 (en) *	2008-05-19	2012-09-25	Cordis Corporation	Extraction of solvents from drug containing polymer reservoirs
JP5542804B2 (ja)	2008-05-23	2014-07-09	ザユニヴァーシティオブブリティッシュコロンビア	リポソームナノ粒子中で使用するための修飾薬物
KR101671537B1 (ko) *	2008-08-11	2016-11-01	넥타르 테라퓨틱스	다분지형 중합체 알카노에이트 컨쥬게이트
US8642063B2 (en)	2008-08-22	2014-02-04	Cook Medical Technologies Llc	Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US9198968B2 (en)	2008-09-15	2015-12-01	The Spectranetics Corporation	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8828925B2 (en)	2008-10-15	2014-09-09	Angiochem Inc.	Etoposide and doxorubicin conjugates for drug delivery
WO2010043047A1 (en)	2008-10-15	2010-04-22	Angiochem Inc.	Conjugates of glp-1 agonists and uses thereof
WO2010063122A1 (en) *	2008-12-05	2010-06-10	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (de)	2008-12-17	2012-08-29	Angiochem Inc	Membrantyp-1-matrixmetalloproteinase-inhibitoren und ihre verwendung
JP2012520314A (ja)	2009-03-11	2012-09-06	アムビトビオスシエンセスコルポラチオン	癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
RU2011146654A (ru)	2009-04-20	2013-05-27	Ангиокем Инк.	Способы лечения рака яичников с применением конъюгированного средства
WO2011000095A1 (en)	2009-07-02	2011-01-06	Angiochem Inc.	Multimeric peptide conjugates and uses thereof
EP2588490B1 (de)	2010-07-02	2017-02-22	Angiochem Inc.	Kurze und d-aminosäure-haltige polypeptide für therapeutische konjugate und ihre verwendungen
US20130331443A1 (en)	2010-12-22	2013-12-12	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en)	2010-12-22	2021-01-19	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20120302954A1 (en)	2011-05-25	2012-11-29	Zhao Jonathon Z	Expandable devices coated with a paclitaxel composition
US20120303115A1 (en)	2011-05-25	2012-11-29	Dadino Ronald C	Expandable devices coated with a rapamycin composition
EP2833905B1 (de)	2012-04-04	2018-05-02	Halozyme, Inc.	Kombinationbehnadlung von hyaluronidase und einem tumor-gerichteten taxane
US9956385B2 (en)	2012-06-28	2018-05-01	The Spectranetics Corporation	Post-processing of a medical device to control morphology and mechanical properties
TWI731535B (zh)	2014-03-21	2021-06-21	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
EP3307326B9 (de)	2015-06-15	2021-02-24	Angiochem Inc.	Verfahren zur behandlung von leptomeningealer karzinomatose
US10517961B2 (en)	2015-09-25	2019-12-31	ZY Therapeutics, Inc.	Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
JP2019526529A (ja)	2016-06-08	2019-09-19	アッヴィ・インコーポレイテッド	抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
MX2018015272A (es)	2016-06-08	2019-08-12	Abbvie Inc	Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CN109641962A (zh)	2016-06-08	2019-04-16	艾伯维公司	抗b7-h3抗体和抗体药物偶联物
WO2017214456A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
RS61828B1 (sr)	2016-06-08	2021-06-30	Abbvie Inc	Anti-b7-h3 antitela i antitelske konjugacije lekova
WO2019222435A1 (en)	2018-05-16	2019-11-21	Halozyme, Inc.	Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN111662250B (zh) *	2019-03-05	2023-12-15	中国医学科学院药物研究所	季铵化修饰紫杉烷衍生物、其药物组合物、其合成途径和用途
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206221A (en) *	1979-01-03	1980-06-03	The United States Of America As Represented By The Secretary Of Agriculture	Cephalomannine and its use in treating leukemic tumors
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Procede de preparation du taxol et du desacetyl-10 taxol
FR2629818B1 (fr) *	1988-04-06	1990-11-16	Centre Nat Rech Scient	Procede de preparation du taxol

1988
- 1988-03-07 US US07/165,173 patent/US4942184A/en not_active Expired - Lifetime
1989
- 1989-02-28 JP JP1503332A patent/JP2680152B2/ja not_active Expired - Lifetime
- 1989-02-28 AU AU32861/89A patent/AU620605B2/en not_active Expired
- 1989-02-28 EP EP89903659A patent/EP0406274B1/de not_active Expired - Lifetime
- 1989-02-28 DE DE68917129T patent/DE68917129T2/de not_active Expired - Lifetime
- 1989-02-28 AT AT89903659T patent/ATE109002T1/de not_active IP Right Cessation
- 1989-02-28 WO PCT/US1989/000810 patent/WO1989008453A1/en not_active Ceased
- 1989-03-06 IL IL8950389A patent/IL89503A/en unknown
- 1989-03-06 CA CA000592894A patent/CA1330436C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2680152B2 (ja)	1997-11-19
DE68917129T2 (de)	1995-03-02
ATE109002T1 (de)	1994-08-15
AU620605B2 (en)	1992-02-20
WO1989008453A1 (en)	1989-09-21
CA1330436C (en)	1994-06-28
AU3286189A (en)	1989-10-05
US4942184A (en)	1990-07-17
EP0406274A4 (en)	1991-08-28
JPH03505725A (ja)	1991-12-12
EP0406274B1 (de)	1994-07-27
IL89503A0 (en)	1989-09-10
EP0406274A1 (de)	1991-01-09
DE68917129D1 (de)	1994-09-01

Legal Events

Date	Code	Title	Description
1999-08-17	KB	Patent renewed
2003-05-29	KB	Patent renewed

Publication	Publication Date	Title
US4942184A (en)	1990-07-17	Water soluble, antineoplastic derivatives of taxol
US5157049A (en)	1992-10-20	Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
Deutsch et al.	1989	Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity
DE69202243T2 (de)	1995-08-31	2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen.
US5422364A (en)	1995-06-06	Water soluble taxol derivatives
WO1994004541A2 (en)	1994-03-03	Protein kinase inhibitors and related compounds combined with taxol
AU713466B2 (en)	1999-12-02	Carbohydrate-modified cytostatics
EP4567039A1 (de)	2025-06-11	Camptothecin-7-ethylaminderivat, herstellungsverfahren dafür und verwendung davon
CN103739616B (zh)	2015-12-30	含噻唑基雷帕霉素类衍生物及其应用
CZ213693A3 (en)	1994-05-18	Diindolepyrrolbenzodiazocines, process of their preparation and use, and a pharmaceutical mixture based thereon
WO2023038088A1 (ja)	2023-03-16	トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法
CN117069696B (zh)	2024-04-26	一种双靶点小分子抑制剂及其制备方法和应用
KR20010013158A (ko)	2001-02-26	세포 증식 억제제로서의 시아노구아니딘
HU217551B (hu)	2000-02-28	6[(2-Hidroxi-etil)-amino-alkil]-5,11-dioxo-5,6-dihidro-11H-indén[1,2-c]izokinolin-származékok, valamint eljárás előállításukra, továbbá hatóanyagként e vegyületeket tartalmazó gyógyászati készítmények
CZ287489B6 (en)	2000-12-13	Taxane derivatives, process of their preparation and pharmaceutical preparation containing thereof
CN114478561B (zh)	2022-12-20	一种依帕司他石蒜碱偶联物及其制备方法和用途
CZ301251B6 (cs)	2009-12-23	Polosyntetické taxany s antitumorovými a antiangiogenními úcinky a jejich použití pro výrobu farmaceutického prostredku
CZ303386B6 (cs)	2012-08-29	N-deacetylthiokolchicinové deriváty
JPH10502088A (ja)	1998-02-24	ブレフェルジンａの新しい誘導体およびがん治療におけるそれらの有用性
CN115894538B (zh)	2025-10-03	一种叶酸偶联含硼化合物的制备方法
DE68920304T2 (de)	1995-05-11	5-substituierte uridinderivate und zwischenprodukte.
US4920126A (en)	1990-04-24	Barbituric acid derivative and treatment of leukemia and tumors therewith
GR1009958B (el)	2021-03-18	Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
JP6708670B2 (ja)	2020-06-10	ステロイド系ラクタムおよびビス（２−クロロエチル）アミノフェノキシプロパン酸誘導体のエステル
CN120647588A (zh)	2025-09-16	一种谷氨酰胺拮抗剂的6-重氮-5-氧代-l-正亮氨酸的前药及其制备方法及应用